1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

Pricing Deals Spell Good News For Exkivity & Vimizin In England

 
• By Neena Brizmohun

Access to Takeda’s lung cancer drug, Exkivity, is being fast-tracked, and BioMarin’s Vimizin, for mucopolysaccharidosis type 4A, is switching to routine use after what the MPS Society called “a long and at times difficult journey.”

Pile of British money pounds sterling new one pound coins GBP in four piles close-up with NHS above. Rising cost of National Health Service concept UK
The NHS says the deals it has struck make the drugs affordable • Source: Alamy

Exkivity (mobocertinib) is to be fast-tracked to eligible lung cancer patients in England within weeks, and Vimizin (elosulfase alfa) will now be made routinely available for treating a rare life-limiting metabolic disorder, after the National Health Service brokered pricing deals for the drugs.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Europe

Non-Submissions To England’s NICE Surge Across All Disease Areas

 
• By Leela Barham

Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.

UK Mandates Unmodified Standardized Contracts To Speed Clinical Trial Set-Up

 
• By Vibha Sharma

The policy expectation that the model clinical trial agreements are used without modification is in line requests from industry and the NHS/HSC.

New EU Filings

 
• By Neena Brizmohun

Plozasiran, Arrowhead Pharmaceuticals' treatment for familial chylomicronemia syndrome, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.